Comparison of Vaginal Versus Sublingual Misoprostol in the Treatment of First-Trimester Missed Miscarriages
Keywords:
Miscarriage, Misoprostol, Mifepristone, Uterine Evacuation, Manual Vacuum Aspiration, Gestational AgeAbstract
OBJECTIVES
To evaluate the efficacy of sublingual versus vaginal misoprostol for the treatment of missed miscarriages in the first trimester of pregnancy.
METHODOLOGY
The gynecology and obstetrics department of Khyber Teaching Hospital in Peshawar conducted this Randomized Controlled Trial investigation from January 2021 to December 2023. Two groups of patients were formed, according to the FIGO procedure, based on whether misoprostol was given vaginally or orally. The dosages of 800 micrograms were administered vaginally to the first group and sublingually to the second group every three hours. Patients were observed for vaginal bleeding and evacuation after 24 hours; if neither happened, the dose was repeated.
RESULTS
The groups did not differ statistically (P-value > 0.05). The mean age of the patients (26.56 ± 5.73 versus 25.45 ± 5.63), parity of the patients (3.31 ± 0.56 versus 3.22 ± 0.54), period of gestation (8.85 ± 1.63 versus 9.37 ± 1.48), and time from initiation of induction till expulsion (13.68 ± 3.52 versus 12.94 ± 3.45) were similar in both groups. For a complete miscarriage in the vaginal misoprostol group, more doses (4.28 ± 0.65 vs 3.26 ± 1.23, P-value < 0.05) were needed. In comparison to the vaginal misoprostol group (56%), the sublingual group (91.6%) reported feeling more comfortable (P-value < 0.05) throughout the drug’s administration. The sublingual misoprostol group had a considerably (P-value < 0.05) better success rate (77.66%) compared to the vaginal misoprostol group (56.32%). Such adverse effects as bleeding during menstruation (68.33% versus 93.33%), vaginal bleeding (31.66% versus 84%), and diarrhoea (30.57% vs 59%) had significant (P-value < 0.05) association with sublingual misoprostol.
CONCLUSION
The efficacy of sublingual misoprostol surpasses vaginal misoprostol. Patients are more satisfied and respond more favourably to the sublingual approach.
Downloads
References
Zhang J, Zhou K, Shan D, Luo X. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2022;5(5):122-30
Cubo AM, Soto ZM, Haro D, Perez A, Hernandez Hernandez ME, Doyague MJ, et al. Medical versus surgical treatment of first trimester spontaneous abortion: A cost-minimization analysis. PLoS One. 2019;14(1):e0210449
Linnakaari R, Helle N, Mentula M, Bloigu A, Gissler M, Heikinheimo O. Trends in the incidence, rate, and treatment of miscarriage - nationwide register-study in Finland, 1998–2016. Hum Reprod. 2019;34(11):2120-8
Dehbashi Z, Moosazadeh M, Afshari M. Comparison between sublingual and vaginal route of misoprostol in management of first trimester miscarriage missing. Mater Sociomed. 2016;28(4):271–3
Park JY, Ahn HJ, Yoo BR, Hwang KR, Lee TS, Jeon HW, et al. Effectiveness and safety of sublingual misoprostol in medical treatment of the 1st trimester miscarriage: experience of off-label use in Korea. Obstet Gynecol Sci. 2018;61(2):220–6
Abubeker FA, Lavelanet A, Rodriguez MI, et al. Medical termination for pregnancy in early first trimester (≤63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review. BMC Womens Health. 2020;20:142
Latif S, Usmani SY, Fatima N. Comparison of sublingual and vaginal routes of misoprostol in termination of first trimester missed abortion. Pak J Med Health Sci. 2014;8(2):123-30
Xu W, Zhang W, Zhang X, Dong T, Zeng H, Fan Q. Association between formaldehyde exposure and miscarriage in Chinese women. Biomed Res Int. 2017;96(26):1434–9
Goldstone P, Walker C, Hawtin K. Efficacy and safety of mifepristone-buccal misoprostol for early medical abortion in an Australian clinical setting. Aust N Z J Obstet Gynaecol. 2017;57(3):366–71
Shrestha D, Aryal S, Safety SB. Efficacy and acceptability of early first trimester abortion using oral mifepristone and sublingual misoprostol. J Nepal Health Res Counc. 2018;16(3):269–73
Schreiber CA, Creinin MD, Atrio J, Sonalkar S, Ratcliffe SJ, Barnhart KT. Mifepristone pretreatment for the medical management of early pregnancy loss. N Engl J Med. 2018;378(23):2161–70
Kapp N, Baldwin MK, Rodriguez MI. Efficacy of medical abortion prior to 6 gestational weeks: a systematic review. Contraception. 2018;97(2):90–9
Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J, et al. The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI). Int J Evid Based Healthc. 2019;17(1):36–43
Bracken H, Zuberi N, de Guevara Puerto AL, Mayi-Tsonga S, Buendía Gómez M, Irfan Ahmed S, et al. Mifepristone and sublingual misoprostol versus sublingual misoprostol alone for missed abortion: results of a randomized placebo-controlled trial. Contraception. 2019;99(5):315–6
Libei D, Wun Raymond RH, Waixiang Y, Yuqi Y, Tingting R, Chung HP. Comparison of the efficacy of 400 μg sublingual misoprostol versus 800 μg vaginal misoprostol for medical abortion in early pregnancy. Chin J Clin Rational Drug Use. 2022;15(1):23–7
Chu JJ, Devall AJ, Beeson LE, Hardy P, Cheed V, Sun Y, et al. Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomized, double-blind, placebo-controlled trial. Lancet. 2020;396(10253):770–8
Stanulov G, Anthoulaki X, Deuteraiou D, Chalkidou A, Tsikouras P, Path W. Comparative study for efficacy of termination in first trimester pregnancy using misoprostol and mifepristone. Arch Community Med Public Health. 2018;4(2):38–46
Schiavo JH. PROSPERO: an international register of systematic review protocols. Med Ref Serv Q. 2019;38(2):171–80
Shimels T, Abraha M, Shafie M, Belay L, Getnet M. Comparison of mifepristone plus misoprostol with misoprostol alone for first trimester medical abortion: a systematic review and meta-analysis protocol. EJRH. 2022;14(2):45–51
Shimels T, Getnet M, Shafie M, Belay L. Comparison of mifepristone plus misoprostol with misoprostol alone for first trimester medical abortion: A systematic review and meta-analysis. Front Glob Womens Health. 2023;4(6):23–6
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Maimoona Qadir
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
